By FDA Lays Out New Psychedelic Framework
Food and Drug Administration (FDA) officials are laying out the agency’s “new framework” for psychedelic medicines, including steps they are taking to “make psychedelic therapies available to patients more quickly, as warranted by the nation’s mental health crisis.” Four FDA staffers wrote in a piece published in the New England Journal of Medicine (NEJM) last week that “the ongoing mental health crisis in the United States continues to worsen.”
The agency “recognizes that although some people benefit from available treatment options, for others our current medications are not enough,” the FDA staffers wrote in the NEJM piece.
“One potential avenue for the development of better treatments includes psychedelic compounds,” they said, noting that substances such as psilocybin and DMT “have been used in traditional healing and spiritual practices since long before the advent of modern psychiatry.”
Decades of Restricted Research
While there has been a “prolonged period of quiescence” in the development of psychedelic medicines for decades, “due to research restrictions,” there has recently been a “dramatic resurgence of interest in psychedelic-based treatment for mental illness and substance use disorders” as a result of “advances in neurobiology and shifting social discourse,” the staffers wrote.
The four FDA authors described the historical gap in psychedelic drug development as a consequence of restrictions on research into these compounds. They wrote that the recent renewal of scientific attention follows progress in understanding how such substances act in the brain, as well as changes in public discussion of the topic.
Guidance for Researchers
In July, FDA published guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. That is part of an “evolving” approach to integrate psychedelics into existing regulatory frameworks for therapeutic drugs, the agency staffers said in the new NEJM piece.
The framework described in the NEJM piece reflects the steps FDA officials said they are taking amid the nation’s mental health crisis.
